KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Assets (2016 - 2025)

Abbott Laboratories' Assets history spans 17 years, with the latest figure at $84.2 billion for Q3 2025.

  • For Q3 2025, Assets rose 13.21% year-over-year to $84.2 billion; the TTM value through Sep 2025 reached $84.2 billion, up 13.21%, while the annual FY2024 figure was $81.4 billion, 11.2% up from the prior year.
  • Assets for Q3 2025 was $84.2 billion at Abbott Laboratories, up from $81.4 billion in the prior quarter.
  • Across five years, Assets topped out at $84.2 billion in Q3 2025 and bottomed at $7.3 billion in Q4 2021.
  • The 5-year median for Assets is $73.3 billion (2021), against an average of $67.5 billion.
  • The largest annual shift saw Assets tumbled 65.35% in 2021 before it soared 816.89% in 2023.
  • A 5-year view of Assets shows it stood at $7.3 billion in 2021, then grew by 9.97% to $8.0 billion in 2022, then skyrocketed by 816.89% to $73.2 billion in 2023, then grew by 11.2% to $81.4 billion in 2024, then rose by 3.4% to $84.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Assets are $84.2 billion (Q3 2025), $81.4 billion (Q1 2025), and $81.4 billion (Q4 2024).